# EDGAR Filing Document

**Accession Number:** 0001635088
**File Stem:** 0000950103-26-007547
**Filing Date:** 2026-5
**Character Count:** 21758
**Document Hash:** b51b635c3410932084dbf0d220f02575
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-26-007547.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0000950103-26-007547

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260520

**DATE AS OF CHANGE**: 20260520

**EFFECTIVENESS DATE**: 20260520

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Roivant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001635088
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981173944
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296071
- **FILM NUMBER:** 261004684

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7TH FLOOR, 50 BROADWAY
- **CITY:** LONDON
- **NON US STATE TERRITORY:** UNITED KINGDOM
- **PROVINCE COUNTRY:** X0
- **ZIP:** SW1H 0DB
- **BUSINESS PHONE:** 441-295-5950

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7TH FLOOR, 50 BROADWAY
- **CITY:** LONDON
- **NON US STATE TERRITORY:** UNITED KINGDOM
- **PROVINCE COUNTRY:** X0
- **ZIP:** SW1H 0DB

**As filed with the Securities and Exchange Commission on May 20, 2026**

**Registration No. 333-______**

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**

**FORM S-8**<br> **REGISTRATION STATEMENT<br> UNDER THE SECURITIES ACT OF 1933** 

**ROIVANT SCIENCES LTD.**<br> (Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Bermuda** | **98-1173944** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**7th Floor<br> 50 Broadway<br> London SW1H 0DB<br> United Kingdom**

**1 Pennsylvania Plaza<br> Floor 54<br> New York, NY 10119<sup></sup> United States<sup>1</sup>**

**Viaduktstrasse 8<br> 4051 Basel<br> Switzerland<sup>1</sup>**

**Telephone: +44 207 400 3347**<br> (Addresses of Principal Executive Offices)

**ROIVANT SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN**<br> (Full Title of the Plan)

**Corporation Service Company<br> 251 Little Falls Drive<br> Wilmington, DE 19808<br> Telephone: (800) 927-9801**<br> (Name and Address for Agent of Service)<br> (Telephone number, Including Area Code, of Agent For Service)

***Copies of all correspondence to:*<br> Derek J. Dostal<br> Stephen A. Byeff<br> Davis Polk & Wardwell LLP<br> 450 Lexington Avenue<br> New York, NY 10017<br> (212) 450-4000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☑ Accelerated filer ☐ <br> Non-accelerated filer ☐ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<sup>1</sup> Addresses of wholly-owned subsidiaries of the Registrant.

**EXPLANATORY NOTE<br> REGISTRATION OF ADDITIONAL SHARES<br> PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E to Form S-8, the Registrant is filing this Registration Statement with the U.S. Securities and Exchange Commission (the "Commission") to register additional shares of the Registrant's Common Stock for issuance under the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "Plan"), pursuant to the provision of the Plan that provides for automatic annual increases in the number of shares reserved for issuance thereunder. This Registration Statement hereby incorporates by reference the contents of the Registrant's registration statement on Form S-8 filed with the Commission on October 8, 2021 (File No. 333-260173), the registration statement on Form S-8 filed with the Commission on June 28, 2022 (File No. 333-265867), the registration statement on Form S-8 filed with the Commission on June 29, 2023 (File No. 333-273000), and the registration statement on Form S-8 filed with the Commission on July 26, 2024 (File No. 333-281061), in each case to the extent not superseded hereby.

**PART I**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act"). In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's annual report on Form 10-K for the fiscal year ended March 31, 2026, filed with the Commission on May 20, 2025 (File No. 001-40782) (the "Annual Report");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant's Annual Report referred to in (a) above; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The description of the Registrant's securities registered pursuant to Section 12 of the Exchange Act (filed as Exhibit 4.2 to the Registrant's Annual Report).

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| Exhibit<br> Number  |  |
| 3.1 | [Memorandum of Association of Roivant Sciences Ltd. (incorporated herein by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-4/A (File No. 333-256165), as amended, filed with the Commission on May 14, 2021)](https://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex31.htm)  |
| 3.2 | [Amended and Restated Bye-laws of Roivant Sciences Ltd. (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-40782), filed with the Commission on October 1, 2021)](https://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/d230641dex31.htm)  |
| 5.1\* | [Opinion of Conyers Dill & Pearman Limited](dp242198_ex0501.htm) |
| 23.1\* | [Consent of Ernst & Young LLP](dp242198_ex2301.htm) |
| 23.2\* | [Consent of Conyers Dill & Pearman Limited (included in Exhibit 5.1)](dp242198_ex0501.htm) |
| 24.1\* | [Power of Attorney (included on the signature page hereto)](#a_001) |
| 99.1 | [Roivant Sciences Ltd. 2021 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the Registrant's Registration Statement on Form S-8 (File No. 333-260173), filed with the Commission on October 8, 2021)](https://www.sec.gov/Archives/edgar/data/1635088/000095010321015700/dp159512_ex9901.htm) |
| 107.1\* | [Filing Fee Table](dp242198_exfilingfees.htm) |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in London, UK, on the 20th day of May 2026.

---

| | |
|:---|:---|
| ROIVANT SCIENCES LTD. | ROIVANT SCIENCES LTD. |
| By: | /s/ Keyur Parekh |
| Name: | Keyur Parekh |
| Title: | Authorized Signatory |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below, constitutes and appoints Richard Pulik, Jo Chen and Keyur Parekh and each or any one of them, our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which said attorneys-in-fact and agents may deem necessary or advisable in order to enable Roivant Sciences Ltd. to comply with the Securities Act of 1933, as amended, and any requirements of the Securities and Exchange Commission in respect thereof, in connection with the filing with the Securities and Exchange Commission of one or more registration statements on Form S-8 under the Securities Act of 1933, as amended, including, specifically, but without limitation, power and authority to sign the name of the undersigned to any such registration statement, and any amendments to any such registration statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/ Matthew Gline | Chief Executive Officer & Director | May 20, 2026 |
| Matthew Gline | (principal executive officer) |  |
| /s/ Richard Pulik | Chief Financial Officer | May 20, 2026 |
| Richard Pulik | (principal financial officer) |  |
| /s/ Jenni Humes | Chief Accounting Officer | May 20, 2026 |
| Jenni Humes | (principal accounting officer) |  |
| /s/ Keith Manchester | Director | May 20, 2026 |
| Keith Manchester |  |  |
| /s/ Ilan Oren | Director | May 20, 2026 |
| Ilan Oren |  |  |
| /s/ Daniel Gold | Director | May 20, 2026 |
| Daniel Gold |  |  |
| /s/ Melissa Epperly | Director | May 20, 2026 |
| Melissa Epperly |  |  |
| /s/ Meghan FitzGerald | Director | May 20, 2026 |
| Meghan FitzGerald |  |  |
| /s/ James C. Momtazee | Director | May 20, 2026 |
| James C. Momtazee |  |  |
| /s/ Mayukh Sukhatme | Director | May 20, 2026 |
| Mayukh Sukhatme |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](image_001.jpg) | **CONYERS DILL & PEARMAN LIMITED**<br>Clarendon House, 2 Church Street<br> Hamilton HM 11, Bermuda<br>Mail: PO Box HM 666, Hamilton HM CX, Bermuda<br> T +1 441 295 1422<br>**conyers.com** |

---

20 May 2026

Matter No.: 348706<br> 44 20 7562 0346<br> <u>karoline.tauschke@conyers.com</u>

Roivant Sciences Ltd.

7<sup>th</sup> Floor

50 Broadway

London SW1H 0DB

United Kingdom

Dear Sirs,

**Re: Roivant Sciences Ltd. (the "Company")**

We have acted as special Bermuda legal counsel to the Company in connection with a registration statement on Form S-8 filed with the U.S. Securities and Exchange Commission (the "**Commission**") on 20 May 2026 (the "**Registration Statement**", which term does not include any other document or agreement whether or not specifically referred to therein or attached as an exhibit or schedule thereto) relating to the registration under the U.S. Securities Act of 1933, as amended, (the "**Securities Act**") of an aggregate of (i) 34,796,916 common shares, par value US$0.0000000341740141 per share, each issuable pursuant to Section 3(a) of the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "**Plan**") providing for an automatic increase in the number of shares reserved for issuance thereunder as of April 1 of each year, and (ii) pursuant to Rule 416(a) under the Securities Act, under the Plan by reason of any stock dividend, stock split or other similar transaction (all such Shares, the "**Shares**").

1. DOCUMENTS
 REVIEWED

For the purposes of giving this opinion, we have examined electronic copies of the following documents:

1.1. the
 Registration Statement; and

1.2. the
 Plan.

We have also reviewed:

1.3. the
memorandum of association and the bye-laws of the Company, each certified by the Secretary of the Company on 18 May 2026; and

1.4. minutes of a meeting of its board of directors held on 30 April 2021,
 unanimous written resolutions of its directors dated 14 May 2021, 24 July 2024, and 31 March 2025 and written
 resolutions of its members dated 1 May 2021 and 29 September 2021, each as certified by the Secretary of the Company on 18 May 2026
 and an extract of minutes of a meeting of its board of directors held 25 February 2026, certified by an officer of the Company on 25 February
2026 (collectively, the "**Resolutions** "); and

1.5 such other documents and made
such enquiries as to questions of law as we have deemed necessary in order to render the opinion set forth below.

2. ASSUMPTIONS

We have assumed:

2.1. the
 genuineness and authenticity of all signatures and the conformity to the originals of all
 copies (whether or not certified) of all documents examined by us and the accuracy, authenticity
 and completeness of the originals from which such copies were taken;

2.2. that
 where a document has been examined by us in draft form, it will be or has been executed and/or
 filed in the form of that draft, and where a number of drafts of a document have been examined
 by us all changes thereto have been marked or otherwise drawn to our attention;

2.3. the
 accuracy and completeness of all factual representations made in the Registration Statement,
 the Plan and other documents reviewed by us;

2.4. that
 the Resolutions were passed at one or more duly convened, constituted and quorate meetings,
 or by unanimous written resolutions, remain in full force and effect and have not been rescinded
 or amended;

2.5. that
 there is no provision of the law of any jurisdiction, other than Bermuda, which would have
 any implication in relation to the opinions expressed herein;

2.6. the
 validity and binding effect of the Plan in accordance with its
 terms under the laws of the State of New York, except for those matters thereunder
 subject to The Companies Act 1981 of Bermuda, as amended (the "**Companies Act** "),
 of which the validity and binding effect shall be governed by Bermuda law;

2.7. that
 there is no provision of any award agreement which would have any implication in relation
 to the opinions expressed herein;

2.8. that,
 upon the issue of any Shares, the Company will receive consideration for the full issue price
 thereof which shall be equal to at least the par value thereof;

2.9. that
 on the date of issuance of any of the Shares the Company will have sufficient authorised
 but unissued common shares; and

2.10. that
 the Company's shares will be listed on an appointed stock exchange, as defined in the
 Companies Act, which includes The Nasdaq Stock Market LLC.

3. QUALIFICATIONS

3.1. We
 have made no investigation of and express no opinion in relation to the laws of any jurisdiction
 other than Bermuda.

3.2. This
 opinion is to be governed by and construed in accordance with the laws of Bermuda and is
 limited to and is given on the basis of the current law and practice in Bermuda.

**conyers.com \| 2**

3.3. This
 opinion is issued solely for the purposes of the filing of the Registration Statement and
 the issuance of the Shares by the Company pursuant to the Plan and is not to be relied upon
 in respect of any other matter.

4. OPINION

On the basis of and subject to the foregoing, we are of the opinion that:

4.1. The
 Company is duly incorporated and existing under the laws of Bermuda in good standing (meaning
 solely that it has not failed to make any filing with any Bermuda government authority or
 to pay any Bermuda government fees or tax which would make it liable to be struck off the
 Register of Companies and thereby cease to exist under the laws of Bermuda).

4.2. When
 issued and paid for in accordance with the terms of the Plan, the Shares will be validly
 issued, fully paid and non-assessable (which term means when used herein that no further
 sums are required to be paid by the holders thereof in connection with the issue of such
 shares).

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not hereby admit that we are experts within the meaning of Section 11 of the Securities Act or that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission promulgated thereunder.

Yours faithfully,

**/s/** Conyers Dill & Pearman Limited**

**conyers.com \| 3**

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Roivant Sciences Ltd. 2021 Equity Incentive Plan of Roivant Sciences Ltd. of our reports dated May 20, 2026, with respect to the consolidated financial statements of Roivant Sciences Ltd. and the effectiveness of internal control over financial reporting of Roivant Sciences Ltd., included in its Annual Report (Form 10-K) for the year ended March 31, 2026, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Iselin, New Jersey

May 20, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**Roivant Sciences Ltd.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common shares, par value $0.0000000341740141 per share, reserved for issuance under the Roivant Sciences Ltd. 2021 Equity Incentive Plan | (1) | Other | 34796916 | $29.17 | $1015026039.72 | 0.0001381 | $140175.10 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $1015026039.72 |  | 140175.10 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $140175.10 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) This Registration Statement on Form S-8 covers (i) 34,796,916 common shares, par value $0.0000000341740141 per share ("Common Shares"), of Roivant Sciences Ltd. (the "Registrant") that were added to the Common Shares authorized for issuance pursuant to the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "Plan") pursuant to the provision of the Plan providing for an automatic increase in the number of shares reserved for issuance thereunder as of April 1 of each year, and (ii) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), any additional Common Shares that may become issuable under the Plan by reason of any share dividend, share split or other similar transaction. Maximum aggregate offering price and amount of registration fee are rounded up to the nearest whole cent. Maximum aggregate offering price is estimated solely for the purpose of determining the registration fee pursuant to Rule 457(h) and Rule 457(c) under the Securities Act, based upon the average of the high and low sales prices for the Common Shares as quoted on The Nasdaq Global Select Market on May 15, 2026 of $29.17 per share.